Search

Displaying results 2831 - 2840 of 10000 in total
  1. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    [A238914] On September 20, 2021, the FDA granted accelerated approval to tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer in adults in whom the disease progressed during … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration

  2. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

  3. Drug

    Streptococcus pneumoniae type 3 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10294
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 3 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae*

    Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADET
  4. Drug

    Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10296
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

    Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADET
  5. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation.

  6. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

  7. Drug

    Cobamamide

    go.drugbank.com/drugs/DB11191
    ApprovedNutraceutical

    in the mitochondria [L2053]. … MeCbl is mainly involved along with folate in hematopoiesis and the growth of the brain during childhood.

    Mixtures: EnLyte Extra-LN
  8. Drug

    Castor oil

    go.drugbank.com/drugs/DB11113
    ApprovedNutraceuticalVet approved

    Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. … Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation [F70].

    Synonyms: Toto ni vavalagi oil
  9. Drug

    Dihydro-alpha-ergocryptine

    go.drugbank.com/drugs/DB11274
    Approved

    Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. … Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049]

  10. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate. … [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]